Sygnia has provided details on its Itrix Solactive Healthcare 150 ETF, which is made to track the performance of the largest 150 companies from the developed market healthcare industry.
On Monday, 16 August 2021, Sygnia provided details of its Sygnia Itrix Solactive Healthcare 150 Exchange Traded Fund (ETF). It is described as a high risk, passively managed index tracking fund, registered as a collective investments scheme listed on the Johannesburg Stock Exchange (JSE).
Sygnia stated that the objective of the fund is to replicate the price and yield performance of the Solactive Developed Markets Healthcare 150 Index as closely as possible, by physically holding a portfolio of securities equivalent to the basket of securities comprising the index and in similar weightings to that of the index. The index is meant to track the performance of the largest 150 companies from the developed market healthcare industry, and is said to be based on the Solactive Global Benchmark Series.
Sygnia further stated that constituents are selected and weighted based on free-float market capitalisation, with index performance data able to be sourced from Solactive, Reuters and Sygnia. In terms of risk management, Sygnia explained that the fund’s focus on the largest, more liquid companies provides an added benefit. Well-known companies the fund is invested in include Johnson & Johnson and Pfizer Inc., amongst others.
See the post below.
More than meets the 👀.
The data is clear: better health equals better living standards and more robust economies.Find out more: https://t.co/j8dWAADtvF pic.twitter.com/JshEEb9ip4
— Sygnia (@sygnia) August 16, 2021
